On October 28, 2026, GT Metabolic™ Solutions, a pioneer in the medical device field and the first to receive FDA De Novo grant and 510(k) clearance for use of magnetic technology to create compression anastomoses (connections between two tubular structures in the body, such as intestines), announced a Series C growth investment from J.P. Morgan Life Sciences Private Capital. Wilson Sonsini Goodrich & Rosati advised GT Metabolic on the transaction.

Proceeds from the financing will support the company’s ongoing global commercial launch and fund expansion into new surgical and therapeutic settings.

The Wilson Sonsini team that advised GT Metabolic on the transaction includes Elton Satusky, Daniel Cho, Kevin Roesser, Seth Cowell, and Anne Seymour.

For more information, please see GT Metabolic's news release.